Spectral Instruments Imaging manufactures instruments for preclinical optical (bioluminescent, fluorescent) and X-ray imaging.
![Cellular analysis](https://www.accela.eu/files/fields/2/cellular-analysis-hex.jpg)
Automated microscopy and Spatial Proteomics
Real-time, label free cell analysis
Nano and micro particle analysis
![Flow cytometry](https://www.accela.eu/files/fields/3/flow-cytometry-hex.jpg)
Accelerate to discover
Related topics
Theranostics: From Mice to Men and Back
Jun 25, 2024
Recorded webinar
Presenters: Prof. Dr. Ken Herrmann and Prof. Dr. Katharina Lückerath – Moderator: Hannah Notebaert
Orion 2024 AACR poster: 17-plex single-step stain and imaging of cell Lung Carcinoma
Jun 21, 2024
RareCyte Orion is a benchtop, high resolution, whole slide multimodal imaging instrument. A combination of quantitative...
Hypoxia in the Tumor Immune Microenvironment (TIME)
Jun 6, 2024
Thursday, 11 July 2024, 16:00 CET | 10:00 EST
Zaver M. Bhujwalla, PhD
...
X-RAD 320 for irradiation therapy during quantifying study for in vivo collagen reorganization
Jun 5, 2024
Quantifying in vivo collagen reorganization during immunotherapy in murine melanoma with second harmonic generation...
Use of MRI and microCT to evaluate gene therapy for the treatment of discogenic back pain
Jun 4, 2024
MRI images were obtained using the 9.4T Bruker BioSpec system, equipped with 40 mm 1H quadrature volume resonator, and...
Exosome-Mediated Delivery of Small Molecules, RNA & DNA for Development of Novel Cancer Therapeutics
Jun 3, 2024
Disha Moholkar of University of Louisville's Gupta Lab
Tuesday, June 11, 2024, 6:30 PM...
Emulate in vivo conditions – introduce shear flow to your experiments with BioFlux system
May 27, 2024
Most research is still conducted in vitro without the presence of flow. We use the BioFlux System to give you the...
High-frequency Ultrasound System For Preclinical Imaging
May 13, 2024
The Prospect T1 is an innovative high-frequency ultrasound system designed specifically for in vivo preclinical imaging...
Apr 1, 2020
This study identifies Notch1 as a therapeutic target in prostate cancer. Loss of NOTCH1 in aggressive prostate cancer cells decreases proliferation, invasion, and tumorsphere formation. Therapeutic inhibition of Notch1 activity with gamma secretase inhibitors RO4929097 or DAPT in prostate cancer cells further results in decreased proliferative abilities. Loss of NOTCH1 and treatment of immunocompromised mice bearing prostate cancer xenografts with RO4929097 display significantly impaired tumor growth. Loss of NOTCH1 additionally decreased metastatic potential of prostate cancer cells in invasion assays in vitro as well as in vivo experiments. Moreover, treatment with gamma secretase inhibitors or NOTCH1 gene deletion synergized with antiandrogen therapies, enzalutamide or abiraterone, to decrease the growth of prostate cancer cells. Combination of gamma secretase inhibitors with abiraterone significantly inhibited cell migration and invasion, while combination with enzalutamide reversed enzalutamide-induced migration and invasion. These collective findings suggest loss of NOTCH1 delays growth of CRPC and inhibits metastasis, and inhibition of Notch1 activation in conjunction with second-generation antiandrogen therapies could delay growth and progression of prostate cancer.
Related technologies: Fluorescence, luminescence, X-ray, radiographic imaging
Get more info
Brand profile
Spectral Instruments Imaging manufactures instruments for preclinical optical (bioluminescent, fluorescent) and X-ray imaging.
More info at:
https://spectralinvivo.com/